Your session is about to expire
← Back to Search
This trial will compare the efficacy of a new quadrivalent influenza modRNA vaccine to a licensed inactivated influenza vaccine in healthy adults 18 years and older.
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2012 Phase 3 trial • 6104 Patients • NCT01346592
Awards & Highlights
Find a Location
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Who is running the clinical trial?
- Group 1: Quadrivalent influenza modRNA vaccine, 18 through 64 years of age
- Group 2: Quadrivalent influenza vaccine, 18 through 64 years of age
- Group 3: Quadrivalent influenza modRNA vaccine, ≥65 years of age
- Group 4: Quadrivalent influenza vaccine, ≥65 years of age
Frequently Asked Questions
Are there any currently open vacancies for this trial?
"Active recruitment is underway for this clinical trial, which was first announced on September 12th, 2022. The most recent update was on October 24th, 2022. At present, the plan is to have 25,000 people enrolled at 100 different locations."
How many participants are being sought for this experiment?
"In order to gain accurate results, this clinical trial requires 25000 participants that match the pre-specified inclusion criteria. patients are able to partake in this study from multiple locations, such as ActivMed Practices & Research, Inc. in Portsmouth, New Hampshire and Ascada Research in Fullerton, California."
What is the purpose of this particular clinical trial?
"The primary objective of this clinical study, as stated by the sponsor, pharmaceutical company Pfizer, is to compare the rate of adverse events 4 weeks post-vaccination in adults aged 18-64 and those aged 65 and over. Additionally, this trial will compare the following secondary outcomes: the percentage of participants with a HAI titer of 1:40 or higher for each strain, the rate of seroconversion for each A strain between qIRV and QIV recipients, and the HAI geometric mean fold rise for each strain in adults aged 18-64 and those aged 65 and over."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
What questions have other patients asked about this trial?
How responsive is this trial?
Most responsive sites:
- WR-Global Medical Research, LLC: < 24 hours
- Sugar Lakes Family Practice: < 24 hours
- Diablo Clinical Research, Inc.: < 24 hours
Typically responds via
Average response time
- < 2 Days
Share this study with friends